SCHEMBL5500710

SCHEMBL5500710

COc1cccc(/C=C/c2ccccc2)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 10/20 1.00
CYP19A1 P11511 2/20 0.73
TRPA1 O75762 1/20 0.73
KDM4E B2RXH2 1/20 0.71
MAPT P10636 1/20 0.71
HSD17B10 Q99714 1/20 0.71
CYP1A1 P04798 4/20 0.69
CYP1A2 P05177 4/20 0.69
CYP1B1 Q16678 4/20 0.69
TUBB4A P04350 1/20 0.61
TUBB P07437 1/20 0.61
TUBA3C P0DPH7 1/20 0.61
TUBA1B P68363 1/20 0.61
TUBA4A P68366 1/20 0.61
TUBB4B P68371 1/20 0.61
TUBB3 Q13509 1/20 0.61
TUBB2A Q13885 1/20 0.61
TUBB8 Q3ZCM7 1/20 0.61
TUBA3E Q6PEY2 1/20 0.61
TUBA1A Q71U36 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1603723 1.00 NFE2L2 (1.00) NFE2L2CYP19A1TRPA1KDM4EMAPT
Phenol SCHEMBL16930394 0.92 NFE2L2 (0.85) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL118591 0.89 NFE2L2 (0.79) NFE2L2CYP19A1KDM4EMAPTHSD17B10
SCHEMBL615385 0.87 NFE2L2 (0.77) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL20995880 0.86 NFE2L2 (1.00) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL20995868 0.86 NFE2L2 (1.00) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL20995869 0.86 NFE2L2 (1.00) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL20995881 0.86 NFE2L2 (1.00) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL5496221 0.86 NFE2L2 (0.77) NFE2L2CYP19A1TRPA1KDM4EMAPT
SCHEMBL5496229 0.86 NFE2L2 (0.77) NFE2L2CYP19A1TRPA1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114956965-A Stilbene compound separated from lindera reflexa hemsl and preparation method and application thereof 河南中医药大学 2022-08-30 CN disclosed
US-20220023172-A1 COSMETIC COMPOSITIONS AND METHODS OF USE TRUJILLO KRISTINA (US) 2022-01-27 US disclosed
US-20200397676-A1 COSMETIC COMPOSITIONS AND METHODS OF USE K&K BIOTECH (US) 2020-12-24 US disclosed
WO-2020112998-A1 COSMETIC COMPOSITIONS AND METHODS OF USE STC.UNM (US) 2020-06-04 WO disclosed
US-20190160021-A1 Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 STC UNM (US) 2019-05-30 US disclosed
US-9925153-B2 Therapeutic agents for skin diseases and conditions STC.UNM (US) 2018-03-27 US disclosed
US-20160287531-A1 THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS STC.UNM 2016-10-06 US disclosed
US-8980954-B2 Substituted cis- and trans-stilbenes as therapeutic agents STC.UNM (US) 2015-03-17 US disclosed
US-20130178536-A1 SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS STC.UNM (US) 2013-07-11 US disclosed
US-20070249647-A1 Substituted CIS- and trans-stilbenes as therapeutic agents REGENTS OF THE UNIVERSITY OF NEW MEXICO 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160021-A1 Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 NFKBIA, NFE2L2, NFKB2 NFE2L2 2/4885CYP19A1 987/4885TRPA1 1085/4885
US-20160287531-A1 THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS CUTA, TSLP, ELANE NFE2L2 696/4885CYP19A1 564/4885TRPA1 1457/4885
US-20220023172-A1 COSMETIC COMPOSITIONS AND METHODS OF USE NFKBIA, IKBKB, NFKB2 NFE2L2 9/4885CYP19A1 249/4885TRPA1 605/4885
US-20070249647-A1 Substituted CIS- and trans-stilbenes as therapeutic agents TGFB1, VHL, TMSB10 NFE2L2 68/4885CYP19A1 143/4885TRPA1 1533/4885
US-20130178536-A1 SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS PSEN1, TERT, PSEN2 NFE2L2 63/4885CYP19A1 50/4885TRPA1 1056/4885
US-20200397676-A1 COSMETIC COMPOSITIONS AND METHODS OF USE KEAP1, NFE2L2, NQO1 NFE2L2 2/4885CYP19A1 113/4885TRPA1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.